AstraZeneca to add RSV vaccine to pipeline via purchase of Icosavax

12 Dec 2023
firstwordpharma.com
VaccinePhase 2AcquisitionClinical ResultPhase 1
AstraZeneca agreed to acquire Icosavax for up to $1.1 billion, adding the investigational respiratory syncytial virus (RSV) vaccine candidate IVX-A12 to its pipeline. The Phase III-ready, combination protein virus-like particle vaccine targets both RSV and human metapneumovirus (hMPV).
“This virus-like particle vaccine technology has the potential to transform prevention against severe infectious diseases,” remarked Iskra Reic, executive vice president of vaccines and immune therapies at AstraZeneca. Reic said the addition of IVX-A12 gives the company “a differentiated, advanced investigational vaccine, and a platform for further development of combination vaccines against respiratory viruses.”
AstraZeneca already markets the single-dose, long-acting monoclonal antibody Beyfortus (nirsevimab) for the prevention of RSV lower respiratory tract disease in newborns and infants following approval in Europe and the US.
Meanwhile, in a Phase II study, IVX-A12 demonstrated robust immune responses across RSV and hMPV antibodies, with the vaccine generally well tolerated. The shot combines Icosavax’s RSV prefusion F protein VLP vaccine candidate IVX-121 and the company’s hMPV prefusion F protein VLP vaccine candidate IVX-241.
Under the agreed terms, AstraZeneca will acquire all of Icosavax’s outstanding stock for a price of $15 per share in cash, or approximately $800 million, representing a 43% premium to the closing price on December 11. The deal also includes a contingent value right of up to $5 per share in cash related to regulatory and sales milestones. The purchase is expected to close in the first quarter of 2024.
More to come.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.